KDIGO Bundle to Prevent AKI in Sepsis
Study Details
Study Description
Brief Summary
Summary: Controlled, prospective, randomized and randomized clinical trial of two intervention groups (standard care vs. preventive recommendations the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for AKI) of patients diagnosed with sepsis and abdominal post-surgical septic shock with positive results in the risk determination of acute renal injury by NephroCheck® Test that integrates the urinary biomarkers TIMP-2 and IGFBP-7.
Hypothesis: The implementation of a package of preventive measures proposed by the KDIGO guide can reduce the occurrence and severity of acute renal injury in the high-risk abdominal post-surgical septic patient detected by urinary biomarkers for early detection.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: KDIGO guide recommendations Preventive recommendations the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for AKI |
Procedure: Preventive recommendations for kidney disease: guidelines for improving overall outcomes (KDIGO) for AKI
Patients assigned to the treatment group will receive the AKI preventive recommendations from the KDIGO guide: withdraw nephrotoxics, ensure volemia and renal perfusion pressure by means of advanced hemodynamic monitoring-optimization (minimum monitoring objective: Unit algorithm based on volume systolic (VS) by pulse wave analysis - Flotrac® / ClearSight® system - or transpulmonary thermodilution - VolumeView® system -), monitor plasma creatinine and urinary expenditure, avoid hyperglycemia (serum blood glucose target: 110-149 mg / dl), and consider alternatives to diagnostic-therapeutic radiocontrast procedures.
|
No Intervention: Standard care The patients assigned to the control group will receive the current standard care of the septic patients of the Unit according to our protocols |
Outcome Measures
Primary Outcome Measures
- Compare the incidence of moderate-severe acute renal injury [72 hours]
Compare the incidence of moderate-severe acute renal injury (stages KDIGO 2 and 3) in the first 72 hours of diagnosis of sepsis and septic post-surgical septic shock in patients at high risk of AKI determined by NephroCheck® Test (those with a ≥0.3 ng / ml2 / 1000 result) that the package of preventive measures proposed by the KDIGO guideline is applied vs. standard treatment
Secondary Outcome Measures
- Compare mortality from any cause [90 days]
Compare mortality from any cause at 12, 24, 48 and 72 hours, and 30, 60 and 90 days in patients diagnosed with sepsis and abdominal post-surgical septic shock and high risk of AKI determined by NephroCheck® Test (patients with results ≥0.3 ng / ml2 / 1000) that the package of preventive measures proposed by the KDIGO guideline is applied vs. standard treatment
- Compare the number of participants in need of renal replacement therapy [90 days]
Compare the number of participants in need of renal replacement therapy at 12, 24, 48 and 72 hours, and 30, 60 and 90 days in patients diagnosed with sepsis and abdominal post-surgical septic shock and high risk of AKI determined by NephroCheck® Test (those with result ≥0.3 ng / ml2 / 1000) that the package of preventive measures proposed by the KDIGO guideline is applied vs. standard treatment
- Compare the number of participants with persistent renal dysfunction [90 days]
Compare the number of participants with persistent renal dysfunction at 30, 60 and 90 days in patients diagnosed with sepsis and abdominal post-surgical septic shock and high risk of AKI determined by NephroCheck® Test (those with a ≥0.3 ng / ml2 / 1000 result) that the package of preventive measures proposed by the KDIGO guideline is applied vs. standard treatment
- Compare the number of days of stay in the Surgical ICU [90 days]
Compare the number of days of stay in the Surgical ICU in patients diagnosed with sepsis and septic post-surgical septic shock and high risk of AKI determined by NephroCheck® Test (those with a result ≥0.3 ng / ml2 / 1000) that apply the package of preventive measures proposed by the guide KDIGO vs. standard treatment
- Compare the number of days of stay in the hospital [90 days]
Compare the number of days of stay in the hospital in patients diagnosed with sepsis and abdominal post-surgical septic shock and high risk of AKI determined by NephroCheck® Test (those with a result ≥0.3 ng / ml2 / 1000) that apply the package of preventive measures proposed by the KDIGO guide vs. standard treatment
- Measure the incidence of development of AKI in patients at low risk of AKI determined by NephroCheck® Test [72 hours]
Measure the incidence of development of AKI (any KDIGO stage) at 12, 24, 48 and 72 hours after diagnosis of sepsis and septic post-surgical septic shock in patients at low risk of AKI determined by NephroCheck® Test (those with a result of 0.3 ng / ml2 / 1000).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients older than 18 years.
-
Patients (or their informed family members) who accept and sign the informed consent.
-
Patients diagnosed with sepsis or abdominal post-surgical septic shock.
Exclusion Criteria:
-
Patients under 18 years.
-
Patients (or their authorized relatives) who refuse to sign the informed consent.
-
Patients diagnosed with sepsis or non-surgical septic shock.
-
Patients diagnosed with sepsis or septic shock of origin other than abdominal.
-
Patients with AKI stages KDIGO 2 and 3 and / or renal replacement therapy.
-
Patients with chronic renal failure and glomerular filtration <30 ml / min and / or undergoing treatment with dialysis or previous renal transplantation.
-
Patients with AKI of origin other than the diagnosed septic, such as glomerulonephritis or interstitial nephritis, renal artery occlusion and / or postrenal obstruction.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Surgical Intensive Care Unit of the General University Hospital of Elche | Elche | Alicante | Spain | 03203 |
Sponsors and Collaborators
- Hospital General Universitario Elche
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PI 42/2018